Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SGN-75 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | SGN-75 |
| Name | Type | Description |
|---|---|---|
| SGN-75 | DRUG | SGN-75 (IV) in 21- or 28-day cycles; dose range: 0.3-9 mg/kg |
Inclusion Criteria: * Pathologically-confirmed diagnosis of NHL or RCC * Relapsed, refractory, or progressive disease following at least 1 prior systemic therapy * Confirmed CD70 expression * Measurable disease, defined as at least 1 lesion \>1.5 cm in the greatest transverse diameter for patients ...
SGN-75 was studied in renal cell carcinoma, a type of kidney cancer. It was evaluated in a Phase 1 trial that enrolled patients with CD70-positive renal cell carcinoma or non-Hodgkin lymphoma. The program was investigated as an oncology treatment and is not approved for any indication.
SGN-75 was developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the company associated with the clinical development of this oncology asset.
SGN-75 is in Phase 1 development. Its single clinical trial, NCT01015911, was a Phase 1 dose-escalation study that has been completed. SGN-75 is investigational and has not been approved by the FDA for any use.
SGN-75 was evaluated in one clinical trial, NCT01015911, titled a Phase 1 dose-escalation trial of SGN-75 in CD70-positive non-Hodgkin lymphoma or renal cell carcinoma. The study enrolled 58 patients in the United States, was uncontrolled and non-randomized, and is now completed.
Yes. The Phase 1 trial of SGN-75, NCT01015911, specifically enrolled patients with CD70-positive disease, meaning tumor CD70 expression was used to select participants. The study included adults aged 18 years and older with renal cell carcinoma or non-Hodgkin lymphoma.